This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 9.8%
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -10.53% and 360.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in Aurinia (AUPH) Stock
by Zacks Equity Research
Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 6.2%
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Options Traders Expect Huge Moves in Aurinia (AUPH) Stock
by Zacks Equity Research
Investors need to pay close attention to Aurinia (ENPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -13.33% and -45.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Aurinia Pharmaceuticals (AUPH) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 0.00% and 0.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -23.53% and 476.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -18.75% and 447.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) needs Investors to pay close attention to the stock based on moves in the options market lately.
Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session
by Zacks Equity Research
Aurinia Pharmaceuticals saw its shares rise nearly 8% on the day.
Can The Uptrend Continue for Aurinia Pharmaceuticals (AUPH)?
by Zacks Equity Research
Investors certainly have to be happy with Aurinia Pharmaceuticals Inc (AUPH) and its short term performance
Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock
by Zacks Equity Research
Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock on the back of its high implied volatility
Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
by Zacks Equity Research
Investors in Aurinia Pharmaceuticals Inc. (AUPH) need to pay close attention to the stock based on moves in the options market lately.
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.
Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Aurinia Pharmaceuticals Inc. (AUPH) may be one such company.